EWTX NASDAQ
Edgewise Therapeutics, Inc.
1W: +7.2%
1M: -0.2%
3M: +31.7%
YTD: +75.2%
1Y: +184.3%
3Y: +466.8%
5Y: +93.2%
$40.35
-1.25 (-3.00%)
Weekly Expected Move ±10.1%
$33
$37
$41
$45
$49
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.3B
52W Range12.3-48.4
Volume902,387
Avg Volume1,471,095
Beta0.28
Dividend—
Analyst Ratings
Company Info
CEOKevin Koch
Employees154
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-26
Websiteedgewisetx.com
1715 38th Street
Boulder, CO 80303
US
Boulder, CO 80303
US
303 735 8373
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Latest News
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Russell Alan J | S-Sale | 130,352 | $39.41 | 2026-07-01 |
| Russell Alan J | S-Sale | 69,648 | $39.41 | 2026-07-01 |
| Fox Jonathan C | A-Award | 319 | — | 2026-07-01 |
| ROOT JONATHAN D | A-Award | 16,377 | $35.59 | 2026-06-05 |
| Thompson Peter A. | A-Award | 16,377 | $35.59 | 2026-06-05 |